Medgenic's New Chairman Bullish on Platform Technology, Medical Economics, and Expanded Applications
(Thomson Reuters ONE) -
In a rare investor interview, Dr. Sol Barer, newly-named chairman of Medgenics,
Inc. (AMEX:MDGN), made clear his intention of nurturing the company's strong
position in protein therapy by utilizing its platform technology, internally
placed 'biopumps' that target multiple therapeutic indications. Barer
transformed Celgene (NASDAQ:CELG) into one of the first biotech success stories
using a platform technology - the chemical remake of thalidomide into
blockbuster Revlimid - that propelled the stock's market capitalization to
multi-billion dollar levels.
Initial targets for Medgenic's EPODURE, INFRADURE AND HEMODURE are for anemia,
hepatitis and hemophilia, respectively, and have combined markets of roughly
$100 billion. Medgenic's model for protein therapy may, however, have potential
to transcend these three and fulfill Dr. Barer's belief in the technology's far
range of applications. INFRADURE' initial indication, accorded Orphan Drug
status for hepatitis D, is expected to have uses in the entire $20 billion
hepatitis virus market. Further, there has been research in the past linking
protein therapy to conditions such as peripheral neuropathy (numbness) in
diabetics, and multiple sclerosis.
Because Medgenic's technology delivers continuous protein therapy, financial
aspects would be highly beneficial to strained healthcare economies throughout
the world. For example, erythropoietin injections for anemia must now be given
up to three times per week versus a one-time injection with EPODURE. In his
interview, Dr. Barer also recognized favorable pharmacoeconomics and improved
patient well-being as two more of Medgenics' big attractions.
One of the biggest assets that Dr. Barer brings to the emerging firm is his
Rolodex. According to industry observers, since joining the firm, Barer has been
busy introducing the company to potential partners and other industry contacts.
Investors should be aware that developments on this front can not only add
credibility to the technology, but also quickly ramp revenue opportunities up
for the company.
In the near term, a pending clinical development catalyst in the hepatitis C
space also makes the firm worth watching.
About The Analyst: Sharon di Stefano
Sharon di Stefano has spent 20 years as a healthcare analyst, beginning her
career at Smith Barney, Harris Upham & Co. specializing in medical devices,
pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di
Stefano had also served as Senior Venture Officer for the Edison Innovation
Fund, implemented through the New Jersey Economic Development Authority that
provided funding for early-stage life sciences companies.
Ms. di Stefano received a Masters of Science degree, in Business, from Johns
Hopkins University in 1986, and a Bachelor of Arts from the University of
Delaware in 1984 with a minor in biology.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Briefing via Thomson Reuters ONE
[HUG#1631181]
Datum: 01.08.2012 - 15:44 Uhr
Sprache: Deutsch
News-ID 170759
Anzahl Zeichen: 3729
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 242 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medgenic's New Chairman Bullish on Platform Technology, Medical Economics, and Expanded Applications"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Briefing (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
